News Search Results
Jan 06, 2025, 08:30 ET BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
available through the Company's website for a limited time following the conference. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Jan 06, 2025, 08:30 ET Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jan 06, 2025, 08:00 ET Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases
tRNA medicines to patients." Dr. Kreher is an accomplished physician executive and pediatric endocrinologist with a distinguished career in biotechnology, spanning leadership roles in both private and public biotech companies. She has been instrumental in the development and commercialization of therapies
More news about: Alltrna
Jan 06, 2025, 07:59 ET GlycoNex Announces Licensing Agreement for SPD8 Biosimilar
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced a licensing agreement for its denosumab biosimilar,
More news about: GlycoNex, Inc.
Jan 06, 2025, 07:00 ET Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Mass., Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President
More news about: Leap Therapeutics, Inc.
Jan 03, 2025, 17:20 ET Spyre Therapeutics Announces Grants of Inducement Awards
Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy
More news about: Spyre Therapeutics, Inc.
Jan 03, 2025, 13:30 ET Sanitary Pumps Market to Grow by USD 566.6 Million (2025-2029), Demand in Food and Beverage Industry Drives Revenue, AI Redefining Market Landscape - Technavio
Type (Kinetic sanitary pumps and Positive displacement (PD) sanitary pumps), End-user (Food and beverage, Pharmaceutical and biotechnology applications, and Others), and Geography (APAC, North America, Europe, South America, and Middle East and Africa)
More news about: Technavio
Jan 03, 2025, 11:36 ET General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets
Choudhary. General Proximity has assembled a world-class Scientific & Strategic Advisory Board featuring key opinion leaders from top biotechnology and pharmaceutical companies such as Martin Babler (Genentech, Principia, Alumis), Lawrence
More news about: General Proximity
Jan 03, 2025, 11:26 ET Hong Kong Expands Global Tech Presence at CES 2025
of new industrialization for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in
More news about: Hong Kong Tech
Jan 03, 2025, 10:15 ET Cell Therapy and Gene Therapy CDMO Market to Reach USD 11.11 Billion by 2030 | Discover Growth Trends and Insights | Valuates Reports
and the presence of leading biotechnology hubs. North America dominates the market, driven by the presence of major pharmaceutical companies, advanced research institutions, and supportive government initiatives that promote biotechnology innovation. Europe
More news about: Valuates Reports
Jan 03, 2025, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jan 03, 2025, 02:30 ET GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment of Jie Jia, Ph.D., as Chief
More news about: Grit Biotechnology
Jan 03, 2025, 00:30 ET Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option
More news about: Nona Biosciences
Jan 02, 2025, 12:43 ET Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing
More news about: Hanx Biopharmaceutical Co., Ltd.
Jan 02, 2025, 10:25 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jan 02, 2025, 10:00 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
Jefferies downgraded Fortrea, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Fortrea's stock price fell $2.73 per share, or 12.29%, to close at $19.48
More news about: Pomerantz LLP
Dec 31, 2024, 16:30 ET Boqii Announces Fiscal 2025 First Half Unaudited Financial Results
the ordered products without taking into consideration any discounts. The total GMV amount (i) includes GMV of products sold by Nanjing Xingmu Biotechnology Co., Ltd., (ii) excludes products sold through consignment model and (iii) excludes the value of services offered by us. GMV is subject to future
More news about: Boqii Holding Limited
Dec 31, 2024, 10:15 ET TCBP Provides Update on Acquisition Strategy and Current Targets
Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations
More news about: TC BioPharm
Dec 31, 2024, 06:10 ET Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced today that it has entered
More news about: Brii Biosciences Limited
Dec 30, 2024, 08:00 ET BrainStorm Issues 2024 Letter to Shareholders
leadership in cell-based therapies. A Resilient Business and Operational Structures Despite the inherent challenges of the biotechnology sector, including a difficult financing environment, BrainStorm has consistently achieved remarkable outcomes with limited resources. All the accomplishments
More news about: BrainStorm Cell Therapeutics Inc.
Dec 30, 2024, 07:30 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform ZURICH
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Dec 30, 2024, 07:00 ET Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Dec 30, 2024, 06:45 ET Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Dec 30, 2024, 06:30 ET Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Dec 27, 2024, 16:30 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP